CISD1

Across TCGA pan-cancer cohorts, CISD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CISD1 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CISD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CISD1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CISD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.734	0.951	.001	9	view →
GBM	DFS	Tertile	All	0.855	0.682	.011	7	view →
CCRCC	DFS	Quartile	All	0.688	0.929	.022	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
HNSC	OS	Median	III,IV	0.946	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CISD1–PDAC (OS)

Open the PDAC breakdown →